AU2002214609A1 - Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge - Google Patents

Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge

Info

Publication number
AU2002214609A1
AU2002214609A1 AU2002214609A AU1460902A AU2002214609A1 AU 2002214609 A1 AU2002214609 A1 AU 2002214609A1 AU 2002214609 A AU2002214609 A AU 2002214609A AU 1460902 A AU1460902 A AU 1460902A AU 2002214609 A1 AU2002214609 A1 AU 2002214609A1
Authority
AU
Australia
Prior art keywords
oligonucleotides
analogs
synthesis
charge
internucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002214609A
Inventor
Douglas J. Dellinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2002214609A1 publication Critical patent/AU2002214609A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002214609A 2000-10-17 2001-10-16 Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge Abandoned AU2002214609A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/691,824 US6693187B1 (en) 2000-10-17 2000-10-17 Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US09/691,824 2000-10-17
PCT/US2001/032465 WO2002032912A2 (en) 2000-10-17 2001-10-16 Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge

Publications (1)

Publication Number Publication Date
AU2002214609A1 true AU2002214609A1 (en) 2002-04-29

Family

ID=24778125

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002214609A Abandoned AU2002214609A1 (en) 2000-10-17 2001-10-16 Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge

Country Status (4)

Country Link
US (4) US6693187B1 (en)
EP (1) EP1334111A4 (en)
AU (1) AU2002214609A1 (en)
WO (1) WO2002032912A2 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693187B1 (en) 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
US20020197618A1 (en) * 2001-01-20 2002-12-26 Sampson Jeffrey R. Synthesis and amplification of unstructured nucleic acids for rapid sequencing
US7772439B2 (en) * 2004-10-25 2010-08-10 Operon Biotechnologies, Inc. Amino or thiol linker building block for the synthesis of amino- or thiol-functionalized nucleic acids and methods of making and use thereof
ATE491938T1 (en) 2004-10-29 2011-01-15 Japan Science & Tech Agency SUBSTRATE FOR MALDI-TOF-MS AND MASS SPECTROMETRIC METHOD USING THEREOF
US7268006B2 (en) * 2004-12-30 2007-09-11 E.I. Du Pont De Nemours And Company Electronic device including a guest material within a layer and a process for forming the same
US7560417B2 (en) * 2005-01-13 2009-07-14 Wisconsin Alumni Research Foundation Method and apparatus for parallel synthesis of chain molecules such as DNA
US20090075342A1 (en) * 2005-04-26 2009-03-19 Sharon Cload Metabolic profile directed aptamer medicinal chemistry
CA2609788A1 (en) * 2005-04-26 2006-11-02 Coley Pharmaceutical Gmbh Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
US8202985B2 (en) * 2005-10-31 2012-06-19 Agilent Technologies, Inc. Monomer compositions for the synthesis of polynucleotides, methods of synthesis, and methods of deprotection
US8552174B2 (en) * 2005-10-31 2013-10-08 Agilent Technologies, Inc. Solutions, methods, and processes for deprotection of polynucleotides
US8097711B2 (en) * 2006-09-02 2012-01-17 Agilent Technologies, Inc. Thioether substituted aryl carbonate protecting groups
US7999087B2 (en) * 2006-11-15 2011-08-16 Agilent Technologies, Inc. 2′-silyl containing thiocarbonate protecting groups for RNA synthesis
US8242258B2 (en) * 2006-12-03 2012-08-14 Agilent Technologies, Inc. Protecting groups for RNA synthesis
EP1935434A1 (en) * 2006-12-19 2008-06-25 Novosom AG Construction and use of transfection enhancer elements
US7812002B2 (en) 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
DK2476689T3 (en) 2007-05-10 2016-01-18 Agilent Technologies Inc Thiocarbonbeskyttende groups for RNA synthesis
PT2170353E (en) * 2007-05-18 2015-09-16 Adiutide Pharmaceuticals Gmbh Phosphate-modified oligonucleotide analogs with immunostimulatory activity
EP2268316A4 (en) * 2008-03-20 2011-05-25 Quark Pharmaceuticals Inc NOVEL siRNA COMPOUNDS FOR INHIBITING RTP801
WO2009144704A2 (en) * 2008-04-15 2009-12-03 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS FOR INHIBITING NRF2
EP2293800B1 (en) 2008-06-06 2016-10-05 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
EP2143726A1 (en) 2008-07-11 2010-01-13 Novosom AG Nucleic acid comprising zwitterionic nucleotides
US20100076183A1 (en) 2008-09-22 2010-03-25 Dellinger Douglas J Protected monomer and method of final deprotection for rna synthesis
WO2010080452A2 (en) 2008-12-18 2010-07-15 Quark Pharmaceuticals, Inc. siRNA COMPOUNDS AND METHODS OF USE THEREOF
EP2427472B1 (en) 2009-05-05 2016-06-22 Miragen Therapeutics Lipophilic polynucleotide conjugates
JP2012529430A (en) 2009-06-08 2012-11-22 クォーク ファーマシューティカルズ インコーポレーティッド How to treat chronic kidney disease
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
CA2828544A1 (en) 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
CA2832899A1 (en) 2011-04-12 2012-10-18 Beth Israel Deaconess Medical Center, Inc. Micro-rna inhibitors and their uses in disease
SG194901A1 (en) 2011-05-09 2013-12-30 Univ Glasgow Methods of modulating micrornas in the treatment of pulmonary arterial hypertension
WO2013022966A1 (en) 2011-08-11 2013-02-14 Isis Pharmaceuticals, Inc. Linkage modified gapped oligomeric compounds and uses thereof
JP2016528161A (en) 2012-01-12 2016-09-15 クォーク ファーマシューティカルズ インコーポレーティッドＱｕａｒｋ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Combination therapy to treat hearing and balance disorders
CN104619844A (en) 2012-09-12 2015-05-13 夸克制药公司 Double-stranded oligonucleotide molecules to p53 and methods of use thereof
EP2895608B1 (en) 2012-09-12 2018-12-05 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
KR102160389B1 (en) * 2013-08-05 2020-09-28 트위스트 바이오사이언스 코포레이션 De novo synthesized gene libraries
EP3137476B1 (en) 2014-04-28 2019-10-09 Ionis Pharmaceuticals, Inc. Linkage modified oligomeric compounds
EP3177327A4 (en) 2014-08-04 2018-03-14 Miragen Therapeutics, Inc. Inhibitors of myh7b and uses thereof
IL234246A0 (en) 2014-08-21 2014-11-30 Omrix Biopharmaceuticals Ltd Stabilized thrombin
CA2960387A1 (en) 2014-09-08 2016-03-17 MiRagen Therapeutics, Inc. Mir-29 mimics and uses thereof
US10040048B1 (en) 2014-09-25 2018-08-07 Synthego Corporation Automated modular system and method for production of biopolymers
CA2975852A1 (en) 2015-02-04 2016-08-11 Twist Bioscience Corporation Methods and devices for de novo oligonucleic acid assembly
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
WO2016197024A2 (en) 2015-06-05 2016-12-08 MiRagen Therapeutics, Inc. Mir-155 inhibitors for treating cutaneous t cell lymphoma (ctcl)
WO2017049231A1 (en) 2015-09-18 2017-03-23 Twist Bioscience Corporation Oligonucleic acid variant libraries and synthesis thereof
CN113604546A (en) 2015-09-22 2021-11-05 特韦斯特生物科学公司 Flexible substrates for nucleic acid synthesis
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
CA3005434A1 (en) 2015-11-16 2017-05-26 Ohio State Innovation Foundation Methods and compositions for treating disorders and diseases using survival motor neuron (smn) protein
WO2017157950A1 (en) 2016-03-15 2017-09-21 Johann Wolfgang Goethe-Universität Light inducible antisense oligonucleotides for in vivo application
UY37376A (en) 2016-08-26 2018-03-23 Amgen Inc ARNI CONSTRUCTIONS TO INHIBIT EXPRESSION OF ASGR1 AND METHODS FOR USE
EP3516528A4 (en) 2016-09-21 2020-06-24 Twist Bioscience Corporation Nucleic acid based data storage
CN110892485B (en) 2017-02-22 2024-03-22 特韦斯特生物科学公司 Nucleic acid-based data storage
KR20240024357A (en) 2017-10-20 2024-02-23 트위스트 바이오사이언스 코포레이션 Heated nanowells for polynucleotide synthesis
UY38003A (en) 2017-12-12 2019-06-28 Amgen Inc ARNI CONSTRUCTIONS TO INHIBIT THE EXPRESSION OF PNPLA3 AND METHODS OF USE OF THE SAME
CN111448316A (en) * 2017-12-22 2020-07-24 罗氏创新中心哥本哈根有限公司 Novel thiophosphorous acid amides
AU2019234916A1 (en) 2018-03-14 2020-10-15 Beth Israel Deaconess Medical Center Micro-RNA and obesity
GB2590196A (en) 2018-05-18 2021-06-23 Twist Bioscience Corp Polynucleotides, reagents, and methods for nucleic acid hybridization
EP3850096A1 (en) 2018-09-11 2021-07-21 Amgen Inc. Purification methods for guanine-rich oligonucleotides
US20220049252A1 (en) 2018-12-10 2022-02-17 Amgen Inc. CHEMICALLY-MODIFIED RNAi CONSTRUCTS AND USES THEREOF
JP2022511550A (en) 2018-12-10 2022-01-31 アムジエン・インコーポレーテツド RNAi construct to inhibit PNPLA3 expression
JP2022521512A (en) * 2019-02-20 2022-04-08 ロシュ イノベーション センター コペンハーゲン エーエス New phosphoramidite
EP3938506A4 (en) 2019-02-26 2022-12-14 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
WO2020176678A1 (en) 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
WO2020243702A2 (en) 2019-05-30 2020-12-03 Amgen Inc. Rnai constructs for inhibiting scap expression and methods of use thereof
US20220363711A1 (en) 2019-06-25 2022-11-17 Amgen Inc. Purification methods for carbohydrate-linked oligonucleotides
WO2021030613A1 (en) 2019-08-13 2021-02-18 Amgen Inc. Rnai constructs for inhibiting slc30a8 expression and methods of use thereof
CN114555621A (en) 2019-08-15 2022-05-27 Ionis制药公司 Bond-modified oligomeric compounds and uses thereof
WO2021119034A1 (en) 2019-12-09 2021-06-17 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
JP2023519215A (en) 2020-03-23 2023-05-10 アムジエン・インコーポレーテツド Monoclonal antibody against chemically modified nucleic acid and its use
CA3177030A1 (en) 2020-04-27 2021-11-04 Aaron Sato Variant nucleic acid libraries for coronavirus
BR112022024501A2 (en) 2020-06-01 2023-05-09 Amgen Inc RNAI CONSTRUCTS TO INHIBIT THE EXPRESSION OF HSD17B13 AND METHODS OF THEIR USE
KR20230046319A (en) 2020-08-13 2023-04-05 암젠 인크 RNAi constructs and methods for inhibiting MARC1 expression
WO2022086866A1 (en) 2020-10-19 2022-04-28 Twist Bioscience Corporation Methods of synthesizing oligonucleotides using tethered nucleotides
AU2021373780A1 (en) 2020-11-05 2023-06-08 Amgen Inc. METHODS FOR TREATING ATHEROSCLEROTIC CARDIOVASCULAR DISEASE WITH LPA-TARGETED RNAi CONSTRUCTS
AR127184A1 (en) 2021-09-30 2023-12-27 Amgen Inc METHODS FOR SEPARATION OF MOLECULAR SPECIES OF OLIGONUCLEOTIDES RICH IN GUANINE
WO2023059629A1 (en) 2021-10-05 2023-04-13 Amgen Inc. Compositions and methods for enhancing gene silencing activity of oligonucleotide compounds
WO2023069754A2 (en) 2021-10-22 2023-04-27 Amgen Inc. Rnai constructs for inhibiting gpam expression and methods of use thereof
TW202342068A (en) 2022-02-25 2023-11-01 美商安進公司 Methods of preparing high concentration liquid drug substances
US20240084301A1 (en) 2022-07-25 2024-03-14 Amgen Inc. Rnai constructs and methods for inhibiting fam13a expression
EP4353823A1 (en) 2022-10-12 2024-04-17 Resalis Therapeutics S.r.l. Inhibitors of micro-rna 22
WO2024130142A2 (en) 2022-12-16 2024-06-20 Amgen Inc. Rnai constructs for inhibiting ttr expression and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4056673A (en) 1976-07-16 1977-11-01 Hoffmann-La Roche Inc. Phosphonoacetic acid derivatives of nucleosides
US4415732A (en) 1981-03-27 1983-11-15 University Patents, Inc. Phosphoramidite compounds and processes
DE3329892A1 (en) * 1983-08-18 1985-03-07 Köster, Hubert, Prof. Dr., 2000 Hamburg METHOD FOR PRODUCING OLIGONUCLEOTIDES
DE3916871A1 (en) * 1989-05-24 1990-11-29 Boehringer Mannheim Gmbh MODIFIED PHOSPHORAMIDITE PROCESS FOR THE PREPARATION OF MODIFIED NUCLEIC ACIDS
WO1993010140A1 (en) 1991-11-21 1993-05-27 Pharmagenics, Inc. Oligonucleotides having modified anionic moieties
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US6069243A (en) * 1998-10-06 2000-05-30 Isis Pharmaceuticals, Inc. Process for oligonucleotide synthesis
US6121437A (en) * 1999-03-16 2000-09-19 Isis Pharmaceuticals, Inc. Phosphate and thiophosphate protecting groups
US6693187B1 (en) * 2000-10-17 2004-02-17 Lievre Cornu Llc Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge

Also Published As

Publication number Publication date
EP1334111A2 (en) 2003-08-13
WO2002032912A3 (en) 2003-03-13
US20060293511A1 (en) 2006-12-28
WO2002032912A2 (en) 2002-04-25
US7067641B2 (en) 2006-06-27
US8846898B2 (en) 2014-09-30
US6693187B1 (en) 2004-02-17
US20100311960A1 (en) 2010-12-09
US7745591B2 (en) 2010-06-29
EP1334111A4 (en) 2007-01-24
US20040116687A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
AU2002214609A1 (en) Phosphinoamidite carboxylates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge
AU2001273063A1 (en) Stabilized interleukin 2
IL178864A0 (en) 3'-prodrugs of 2'-deoxy-??-l-nucleosides
AU2001291859A1 (en) Use of copolycarbonates
AU2001231045A1 (en) Personal cleansing compositions
AU2001249329A1 (en) Lipoxin analogs and methods for the treatment of periodontal disease
AU2001227057A1 (en) Brilliant cosmetics
AU2001231532A1 (en) Improved interleukin 10
AU2001237992A1 (en) Purification of oligonucleotides
AU2001266225A1 (en) Decondensation of dna
AU2002223648A1 (en) Personal cleansing composition
GB2366254B (en) Child-vehicle pusher's raincover
AU2001227084A1 (en) N-arylhydrazide compounds and use thereof as drugs
AP2003002783A0 (en) Medicament containing activted antihtrombin iii
AU2001232332A1 (en) Leptin-resistance ameliorating agents
IL152996A0 (en) Novel interferon for the treatment of multiple sclerosis
AU2001245953A1 (en) Oncogenic osteomalacia-related gene 1
GB0114231D0 (en) Treatment of multiple sclerosis
AU3809300A (en) Cosmetic towelettes
IL131150A0 (en) Antiperspirant wipes
AU2002248155A1 (en) Cleansing composition
AU2002215923A1 (en) Use of medicaments
AU2001233847A1 (en) Interferon-alpha induced genes
AU7445601A (en) Pharmaceutical composition for the treatment of multiple sclerosis
AU2001261035A1 (en) Tnfr related gene 12